Baseline demographic and clinical characteristics for intervention and control group participants
| Intervention (n=64) | Control (n=66) | |
| Age (years) | ||
| Mean (SD) | 72.0 (8.6) | 70.1 (8.3) |
| Range | 50–87 | 53–89 |
| No of males (%) | 39 (60.9) | 35 (53.0) |
| Years since diagnosis of PD (mean (SD)) | 9.1 (6.4) | 8.2 (6.4) |
| Hoehn and Yahr stage (mean (SD)) | 2.6 (0.9) | 2.4 (0.9) |
| Stage 1 (n (%)) | 4 (6) | 9 (14) |
| Stage 2 (n (%)) | 31 (48) | 28 (42) |
| Stage 3 (n (%)) | 16 (25) | 21 (32) |
| Stage 4 (n (%)) | 13 (20) | 8 (12) |
| Living arrangements (n (%)) | ||
| Alone | 14 (22) | 19 (29) |
| With partner | 48 (75) | 44 (67) |
| With family/friends | 1 (2) | 2 (3) |
| Residential home | 1 (2) | 1 (2) |
| No (%) taking levodopa | 59 (92) | 65 (99) |
| No (%) taking dopamine agonist | 39 (61) | 27 (41) |
| No (%) taking monoamine oxidase inhibitor | 10 (16) | 15 (23) |
| No (%) with orthopaedic comorbidity | 23 (36) | 23 (35) |
| No (%) with cardiac comorbidity | 21 (33) | 25 (38) |
| No (%) with mental health comorbidity | 7 (11) | 10 (15) |
| No (%) receiving physiotherapy for PD | 7 (11) | 2 (3) |
PD, Parkinson's disease.